Medicamen Biotech Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	1,645	1,603	1,779	1,404	1,083	1,107
Other Revenue	75.83	72.21	14.26	4.58	71.55	19.94
Revenue	1,721	1,675	1,793	1,409	1,154	1,127
Revenue Growth (YoY)	-4.52%	-6.56%	27.29%	22.02%	2.42%	-10.21%
Cost of Revenue	852.08	864.86	941.05	734.49	542.07	710.91
Gross Profit	868.89	810.61	852.01	674.19	612.38	416.25
Selling, General & Admin	371.61	353.42	335.17	218.24	155.56	95.99
Other Operating Expenses	318.29	268.61	293.34	215.96	220.16	126.81
Operating Expenses	749.54	692.69	699.44	497.86	433.43	248
Operating Income	119.36	117.92	152.57	176.32	178.96	168.25
Interest Expense	-37.64	-31.56	-43.97	-29.23	-14.01	-10.64
Interest & Investment Income	5.07	5.07	7.24	7.21	1.35	1.53
Currency Exchange Gain (Loss)	7.06	7.06	13.85	14.76	14.49	4.71
Other Non Operating Income (Expenses)	0.28	0.28	0.33	1.29	0.08	0.01
EBT Excluding Unusual Items	94.13	98.78	130.02	170.35	180.87	163.87
Gain (Loss) on Sale of Investments	-	-	-	-	0.02	0.04
Gain (Loss) on Sale of Assets	-	-	0	-0.07	-0.01	-0.01
Pretax Income	94.15	98.8	130.76	170.45	180.95	163.94
Income Tax Expense	22.02	33.24	35.82	23.17	31.97	42.65
Earnings From Continuing Operations	72.13	65.56	94.94	147.29	148.98	121.29
Minority Interest in Earnings	5.53	5.53	14.37	1.16	-	-
Net Income	77.66	71.08	109.31	148.44	148.98	121.29
Net Income to Common	77.66	71.08	109.31	148.44	148.98	121.29
Net Income Growth	5.34%	-34.97%	-26.36%	-0.36%	22.82%	-8.74%
Shares Outstanding (Basic)	13	13	13	13	12	12
Shares Outstanding (Diluted)	13	13	13	13	12	12
Shares Change (YoY)	9.75%	0.44%	0.07%	3.56%	-	0.56%
EPS (Basic)	5.84	5.59	8.63	11.73	12.19	9.93
EPS (Diluted)	5.84	5.59	8.63	11.73	12.19	9.93
EPS Growth	-4.02%	-35.25%	-26.41%	-3.78%	22.82%	-9.24%
Free Cash Flow	-	-103.47	-130.31	-128.94	-44.99	-51.94
Free Cash Flow Per Share	-	-8.14	-10.29	-10.19	-3.68	-4.25
Dividend Per Share	-	1.000	1.000	1.000	1.000	1.000
Dividend Growth	-	-	-	-	-	100.00%
Gross Margin	50.49%	48.38%	47.52%	47.86%	53.04%	36.93%
Operating Margin	6.93%	7.04%	8.51%	12.52%	15.50%	14.93%
Profit Margin	4.51%	4.24%	6.10%	10.54%	12.90%	10.76%
Free Cash Flow Margin	-	-6.18%	-7.27%	-9.15%	-3.90%	-4.61%
EBITDA	188.39	187.02	221.76	238.89	235.68	192.8
EBITDA Margin	10.95%	11.16%	12.37%	16.96%	20.41%	17.11%
D&A For EBITDA	69.04	69.1	69.19	62.56	56.72	24.55
EBIT	119.36	117.92	152.57	176.32	178.96	168.25
EBIT Margin	6.93%	7.04%	8.51%	12.52%	15.50%	14.93%
Effective Tax Rate	23.39%	33.65%	27.39%	13.59%	17.67%	26.01%
Revenue as Reported	1,733	1,688	1,816	1,433	1,172	1,135
Advertising Expenses	-	11.42	14.37	6.83	4.6	0.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.